Please assess the completion status of the following clinical trial:

Trial Title: Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients \> 18 years of age.~* Detectable plasma HCV-RNA by qualitative PCR assay.~* HCV genotype 1 infection,~* Documented recurrent hepatitis C by liver biopsy within the past year.~* On cyclosporine or tacrolimus-based immunosuppression~* Negative urine pregnancy test before initiating the treatment for women of childbearing potential.~* Willingness of the patient and all potentially childbearing partners to use a reliable form of effective contraception during the study, unless the patient or partner is surgically sterile or post-menopausal.~* Willingness to undergo provide informed consent and comply with study requirements.~Exclusion Criteria:~* Genotype non-1 HCV infection.~* Women who are pregnant or breast-feeding.~* Male partners of women who are pregnant.~* Evidence of co-infection with HIV or hepatitis B.~* History of severe psychiatric disease.~* History of immunologically mediated disease (e.g., inflammatory bowel disease, lupus erythematosus, rheumatoid arthritis, etc.)~* History of clinically significant pulmonary disease.~* History of severe cardiac disease.~* History of malignancy where risk of recurrence is \>20% within 2 years.~* History of uncontrolled seizure disorder.~* History of poorly controlled thyroid disease.~* History of poorly controlled diabetes mellitus.~* History of severe retinopathy.~* Active gout.~* History or evidence of severe medical illness that, in the opinion of the investigator, makes the patient unsuitable for pegylated interferon alfa-2a treatment (Pegasys®).~* Inability or unwillingness to abstain from alcohol throughout the entire study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HCV, LT, Pegasys, ribavirin, telaprevir (Type: EXPERIMENTAL): Patients are being asked to be part of this arm because they are orthotopic liver transplant recipients (OLT) and have the Hepatitis C Virus (HCV). They will be given the study drugs Pegasys, ribavirin and telaprevir

Based on this trial design, predict the completion outcome and termination type (if applicable).